Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy.~2. Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.0), assessed using imaging techniques (CT or MRI).~3. HER2 positive tumour (primary tumour or metastasis) as assessed by the central laboratory. (Both IHC and Dual SISH will be performed on all patients in the central laboratory.)~4. ECOG Performance status 0, 1 or 2.~5. Life expectancy of at least 3 months.~6. Male or female. Age ≥ 18 years.~7. Signed informed consent.~Exclusion Criteria:~1. Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study; the total dose of cisplatin should be less than 300mg/m2, adjuvant/neoadjuvant therapy with oxaplatin is not allowed).~2. No prior use of EGFR-targeting drugs,such as Trastuzumab,lapatinib or other TKIs.~3. Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not those with a jejunostomy probe).~4. Patients with active (significant or uncontrolled) gastrointestinal bleeding.~5. Residual relevant toxicity resulting from previous therapy (with the exception of alopecia), e.g. neurological toxicity ≥ grade 2 NCI-CTCAE 4.0.~6. Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.~7. Neutrophil count \< 1.5 × 109/L, or hemoglobin \< 90 g/L,or platelet count \< 100 × 109/L.~8. Serum bilirubin \> 1.5 × upper limit of normal (ULN); or, AST or ALT \> 2.5 × ULN(or \> 5 × ULN in patients with liver metastases); or, alkaline phosphatase \> 2.5 × ULN (or \> 5 × ULN in patients with liver metastases, or \> 10 × ULN in patients with bone but no liver metastases); or, albumin \< 25 g/L.~9. Creatinine clearance \< 60 mL/min.~10. History of documented congestive heart failure; angina pectoris requiring medication;evidence of transmural myocardial infarction on ECG; poorly controlled hypertension (systolic BP \> 180 mmHg or diastolic BP \> 100 mmHg); clinically significant valvular heart disease; or high risk uncontrollable arrhythmias.~11. Baseline LVEF \< 50% (measured by echocardiography or MUGA).~12. Patients with dyspnoea at rest due to complications of advanced malignancy or other disease, or who require supportive oxygen therapy.~13. Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed).~14. Clinically significant hearing abnormality.~15. Known dihydropyrimidine dehydrogenase (DPD) deficiency.~16. History or clinical evidence of brain metastases.~17. Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.~18. Positive serum pregnancy test in women of childbearing potential.~19. Subjects with reproductive potential not willing to use an effective method of contraception.~20. Received any investigational drug treatment within 4 weeks of start of study treatment.~21. Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if palliative radiotherapy given to bone metastastic site peripherally and patient recovered from any acute toxicity;prior adjuvant radiotherapy is allowed if complete at least 6 months ).~22. Major surgery within 4 weeks of start of study treatment, without complete recovery.~23. Patients with known active infection with HIV, HBV, or HCV.~24. Known hypersensitivity to any of the study drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab+Capecitabine+Oxaliplatin (Type: EXPERIMENTAL): Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete